Medical Developments International (ASX:MVP) is delighted to announce that Penthrox has been launched in Italy.
Penthrox is an inhaled medication primarily used to reduce pain following trauma.
A medical trial in Italy with a study of 272 trauma patients in 15 Italian emergency units showed that Penthrox was superior to Standard of Care, including Opioids, for adult trauma pain patients.
MVP CEO John Sharman says “The launch of Penthrox in Italy will trigger another milestone payment from our partner Mundipharma of US$2million which is expected during 2020".
Shares in Medical Developments International (ASX:MVP) are trading 3.1 per cent higher at $5.97.